UBS Group Increases Smith & Nephew (LON:SN) Price Target to GBX 1,860

Smith & Nephew (LON:SN) had its price objective boosted by equities research analysts at UBS Group from GBX 1,800 ($23.68) to GBX 1,860 ($24.47) in a report released on Wednesday, Stock Target Advisor reports. The brokerage presently has a “neutral” rating on the stock. UBS Group’s price target indicates a potential upside of 7.06% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on the stock. Shore Capital restated a “sell” rating on shares of Smith & Nephew in a research note on Thursday, February 20th. Credit Suisse Group cut their price objective on shares of Smith & Nephew from GBX 1,770 ($23.28) to GBX 1,725 ($22.69) and set a “neutral” rating on the stock in a research note on Monday, November 4th. Citigroup initiated coverage on shares of Smith & Nephew in a research note on Thursday, November 21st. They set a “buy” rating on the stock. Goldman Sachs Group cut their price objective on shares of Smith & Nephew from GBX 1,695 ($22.30) to GBX 1,670 ($21.97) and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Smith & Nephew from GBX 1,711 ($22.51) to GBX 1,926 ($25.34) and gave the company a “neutral” rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of GBX 1,946 ($25.60).

Shares of LON SN opened at GBX 1,737.32 ($22.85) on Wednesday. Smith & Nephew has a fifty-two week low of GBX 1,417 ($18.64) and a fifty-two week high of GBX 2,023 ($26.61). The firm’s 50-day simple moving average is GBX 1,871.93 and its 200 day simple moving average is GBX 1,830.86. The company has a quick ratio of 1.03, a current ratio of 2.06 and a debt-to-equity ratio of 39.82. The stock has a market cap of $16.00 billion and a P/E ratio of 25.40.

About Smith & Nephew

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Recommended Story: Technical Indicators – What is a Golden Cross?

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.